MK-677 (Ibutamoren)

MK-677, also known as ibutamoren, is an orally active, non-peptide compound that behaves as a ghrelin-receptor agonist and growth hormone secretagogue. It has been studied as an investigational agent for raising levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), but it has never been approved as a medicine.

A defining feature of MK-677 is that it is a small molecule taken by mouth, which distinguishes it from the injectable secretagogue peptides it is often grouped with. Claims made about it in commercial and wellness settings frequently extend well beyond the formal clinical evidence.

MK-677 is described as mimicking the action of ghrelin at the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus. High-level themes include:

• Prompting the pituitary to release the body's own growth hormone rather than supplying GH directly
• Downstream effects on IGF-1, which mediates much of GH's activity
• Preserving a more pulsatile pattern of GH release, a recurring theme in secretagogue research

Because it is a non-peptide small molecule with oral bioavailability, MK-677 is mechanistically distinct from the injectable peptide secretagogues that act on the same receptor family. How these signalling effects translate into meaningful long-term outcomes in people remains an area of ongoing study.

MK-677 is not an approved medicine in major jurisdictions. It has been examined in research settings for conditions associated with low GH signalling, such as muscle wasting and changes in body composition in older adults, but these investigations did not lead to regulatory approval.

In practice it most often appears in experimental protocols or in research-chemical and wellness-oriented products. Because regulatory status, product quality, and evidence strength vary widely, any consideration of MK-677 should be grounded in local regulations and a clear distinction between exploratory research and established therapy.

MK-677 (ibutamoren) is prohibited by the World Anti-Doping Agency at all times, in and out of competition. As a growth hormone secretagogue, it falls within the category covering growth hormone releasing factors and their mimetics.

Athletes subject to anti-doping rules should treat MK-677 as a prohibited substance regardless of how it is marketed or sold.

Commonly discussed effects reflect its GH- and ghrelin-related activity and include increased appetite, water retention or a sense of puffiness, and lethargy or fatigue. A frequently raised metabolic concern is a rise in fasting glucose and reduced insulin sensitivity, which is relevant to people with or at risk of glucose-handling problems.

Robust long-term safety data across diverse populations are limited, and sustained elevation of GH and IGF-1 carries theoretical risks that are better characterised for recombinant growth hormone than for secretagogues. Product sourcing, purity, and individual risk factors all warrant careful attention.

MK-677 is notable pharmacologically for being orally active and relatively long-acting compared with short-acting injectable secretagogues, which is why it is often discussed in terms of once-daily conceptual exposure rather than pulsed injections.

This section describes concepts only. It intentionally does not provide doses, frequencies, or protocols, and it does not constitute medical advice.

In catalogs, MK-677 typically appears as an oral formulation, such as a capsule or a solution, rather than a lyophilized powder for injection. It is sometimes positioned alongside injectable secretagogue peptides because they share a receptor target, even though the route and pharmacology differ.

Structural listings in this catalog are organizational and should not be read as endorsements of specific combinations, regimens, or use cases.

Research on MK-677 has examined its ability to raise GH and IGF-1 and its effects on endpoints such as body composition, appetite, and markers of metabolism, including in older adults and in wasting-related contexts. These studies established reliable short-term hormonal effects but did not translate into an approved therapy.

Because much of the evidence is short-term and outcomes such as glucose changes complicate the risk-benefit picture, claims about MK-677 should be interpreted cautiously. High-level overviews are not a substitute for critical appraisal of primary data.

For deeper dives on this compound, see:

• MK-677 benefits and areas of interest
• MK-677 side effects and safety context
• MK-677 dosing concepts (educational)
• MK-677 research and evidence overview

Future FAQs may cover high-level questions such as how MK-677 differs from injectable secretagogue peptides, why an oral small molecule is grouped with peptides at all, what regulators have said about its marketing, and how clinicians weigh raised GH/IGF-1 against metabolic side effects like changes in fasting glucose. Answers will remain educational and non-prescriptive.